Clinigen Group PLC (LON:CLIN)’s stock price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $931.51 and traded as low as $870.00. Clinigen Group shares last traded at $875.00, with a volume of 97,823 shares trading hands.
A number of brokerages recently issued reports on CLIN. Peel Hunt reissued a “buy” rating and issued a GBX 1,280 ($16.73) price objective on shares of Clinigen Group in a research note on Tuesday, October 15th. Peel Hunt reissued a “buy” rating on shares of Clinigen Group in a research note on Monday, November 4th. Finally, Liberum Capital reissued a “hold” rating on shares of Clinigen Group in a research note on Friday, November 15th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of GBX 1,295 ($16.92).
The company has a debt-to-equity ratio of 76.62, a current ratio of 0.95 and a quick ratio of 0.67. The stock has a market cap of $1.16 billion and a price-to-earnings ratio of 218.75. The business’s 50-day simple moving average is GBX 837.21 and its two-hundred day simple moving average is GBX 931.51.
In related news, insider Nick Keher bought 3,900 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were purchased at an average price of GBX 893 ($11.67) per share, for a total transaction of £34,827 ($45,507.64).
About Clinigen Group (LON:CLIN)
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
Recommended Story: Call Option Volume
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.